[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357009-105":59,"doc-detail-357009-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","adamdec1-predicts-prognosis-and-immunotherapy-response-in-a-pan-cancer-study-with-experimental-validation","ADAMDEC1 predicts prognosis and immunotherapy response in a pan-cancer study with experimental validation","","Background ADAMDEC1, a disintegrin and metalloproteinase domain-like protein decysin-1, is linked to immune disorders and cancers, yet its pan-cancer role is unclear. Methods ADAMDEC1 expression and outcomes were assessed across TCGA, GTEx, GEO, and METABRIC; single-cell RNA-seq, genomic alterations, and pathway programs were analyzed, and immunohistochemistry validated ESCA tissue microarrays. Immunotherapy response was predicted using TIDE and independent cohorts. Results show dysregulation with context-dependent prognosis and immune associations. Conclusions ADAMDEC1 acts as a context-dependent immune regulator and biomarker candidate for precision oncology.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/adamdec1-predicts-prognosis-and-immunotherapy-response-in-a-pan-cancer-study-with-experimental-validation/357009/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/adamdec1-predicts-prognosis-and-immunotherapy-response-in-a-pan-cancer-study-with-experimental-validation/357009.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is ADAMDEC1 and why is it important for cancer research?","Question",{"text":112,"@type":113},"ADAMDEC1 is a disintegrin and metalloproteinase domain-like protein decysin-1. The study notes links to immune disorders and cancers, motivating evaluation of its role across many tumor types.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was ADAMDEC1 analyzed across cancers and what data sources were used?",{"text":117,"@type":113},"ADAMDEC1 expression, prognosis, immune infiltration, and therapy response were analyzed using TCGA, GTEx, GEO, and METABRIC. Single-cell RNA sequencing, genomic alterations, DNA methylation, and gene set enrichment analysis were also included.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about prognosis and immunotherapy response?",{"text":121,"@type":113},"ADAMDEC1 showed dysregulation with context-dependent prognosis, and it correlated with immune infiltration and immunomodulatory genes including PD-1. In esophageal cancer, ADAMDEC1 increased in metastasis and aligned with PD-1, and it predicted immunotherapy response comparably to conventional biomarkers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},357009,1790244162,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Lin et al. Discover Oncology (2026) 17:855 [https://doi.org/10.1007/s12672-026-04977-3](https://doi.org/10.1007/s12672-026-04977-3)  \nDiscover Oncology  \nRESEARCH Open Access  \nADAMDEC1 predicts prognosis   \nand immunotherapy response in a pan-cancer study with experimental validation  \nShuchen Lin1†, Hui Cong1†, Zhen Li1, Lihua Zhang1, Xinmiao Yang1 and Jie Fu1*  \n†Shuchen Lin and Hui Cong contributed equally to this work and share first authorship  \n*Correspondence:  \nJie Fu  \n[fujie74@sjtu.edu.cn](fujie74@sjtu.edu.cn)[ ](fujie74@sjtu.edu.cn)1Department of Radiation Oncology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, \\# 600 Yi Shan Rd, Shanghai  \n200233, People’s Republic of China  \nAbstract  \nBackground ADAMDEC1 (a disintegrin and metalloproteinase domain-like protein decysin-1) is linked to immune disorders and cancers, but its pan-cancer role remains unclear.  \nMethods We analyzed ADAMDEC1 using The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) for expression, prognosis, immune infiltration, and therapy response. Single-cell RNA sequencing (scRNA-seq) and genomic alterations were examined. Gene set enrichment analysis (GSEA) assessed pathways. Immunohistochemistry (IHC) validated ADAMDEC1 in esophageal cancer (ESCA) tissue microarray (n = 48) . Immunotherapy response was predicted using Tumor Immune Dysfunction and Exclusion (TIDE) and independent cohorts.  \nResults ADAMDEC1 was dysregulated across cancers with context-dependent prognosis: high expression correlated with poor survival in lower-grade glioma (LGG) and uveal melanoma (UVM), but better outcomes in ovarian cancer (OV) and skin cutaneous melanoma (SKCM) . Single-cell analysis revealed a dichotomy: in UVM, ADAMDEC1 was mainly in tumor-associated macrophages; in SKCM, it was broadly expressed across malignant, immune, and stromal cells. DNA methylation inversely correlated with expression in 20 cancers. ADAMDEC1 linked to immune infiltration and immunomodulatory genes including programmed cell death protein 1 (PD- 1) . In ESCA, ADAMDEC1 was elevated in metastasis and positively correlated with PD-1 . ADAMDEC1 predicted immunotherapy response comparably to conventional biomarkers.  \nConclusions ADAMDEC1 is a context-dependent immune regulator with prognostic direction determined by cellular origin, supporting its investigation as a therapeutic target and biomarker in precision oncology.  \nKeywords Pan-cancer, ADAMDEC1, Prognosis, Immunotherapy, Markers  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by-nc-nd/4.0/.  \n1 Introduction  \nCancer continues to be a major global source of disease and mortality, exerting substantial detrimental effects on both public health and economic stability [1]. Nowadays, surgery, chemotherapy, radiation, targeted therapy, and immunotherapy are common cancer treatments. Despite considerable ad","cbCaivJfqPhS7aOZ","https://ap.wps.com/l/cbCaivJfqPhS7aOZ","pdf",5646737,24,"English","# Abstract\n# Introduction\n## Cancer burden and treatment landscape\n## Immunotherapy and immune checkpoint inhibitors\n## Rationale for ADAMDEC1 in immunity","[{\"question\":\"What is ADAMDEC1 and why is it important for cancer research?\",\"answer\":\"ADAMDEC1 is a disintegrin and metalloproteinase domain-like protein decysin-1. The study notes links to immune disorders and cancers, motivating evaluation of its role across many tumor types.\"},{\"question\":\"How was ADAMDEC1 analyzed across cancers and what data sources were used?\",\"answer\":\"ADAMDEC1 expression, prognosis, immune infiltration, and therapy response were analyzed using TCGA, GTEx, GEO, and METABRIC. Single-cell RNA sequencing, genomic alterations, DNA methylation, and gene set enrichment analysis were also included.\"},{\"question\":\"What did the study find about prognosis and immunotherapy response?\",\"answer\":\"ADAMDEC1 showed dysregulation with context-dependent prognosis, and it correlated with immune infiltration and immunomodulatory genes including PD-1. In esophageal cancer, ADAMDEC1 increased in metastasis and aligned with PD-1, and it predicted immunotherapy response comparably to conventional biomarkers.\"}]","ADAMDEC1 predicts prognosis and immunotherapy response in a pan-cancer study with experimental validation | PDF",1790128598,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee70ae82765aaa4dda86d5c2d0a4c253.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0587928c5d575dd4774d9bf5d9158cc7.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/566ddd1950c2fe06428b048f38c4c305.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ef6907c87cf4d96f37f5b3e84bfbd0d.webp",980,1306]